NVO Projected Dividend Yield
ADR/Novo-Nordisk AS ( NYSE : NVO )Novo-Nordisk is a healthcare company focuses on diabetes care. Co. is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two segments: diabetes and obesity care and biopharm. Co. has one diabetes product portfolios, including insulin, a portfolio of modern insulin and human insulin as well as a portfolio of GLP-1 receptor agonists administered both via subcutaneous injection and as a tablet. Co.'s first product to treat obesity is Saxenda®. Co.'s second obesity treatment product is Wegovy®. In addition, Co.'s marketed portfolio includes haemophilia and growth hormone therapies. 29 YEAR PERFORMANCE RESULTS |
NVO Dividend History Detail NVO Dividend News NVO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
2024 |
N/A |
Aug 16, 2024 |
Aug 16, 2024 |
Aug 26, 2024 |
0.3623 |
2024 |
N/A |
Mar 22, 2024 |
Mar 25, 2024 |
Apr 02, 2024 |
0.6634 |
2024 Total: |
1.0258 |
||||
2023 |
N/A |
Aug 18, 2023 |
Aug 21, 2023 |
Aug 29, 2023 |
0.3124 |
2023 |
N/A |
Mar 24, 2023 |
Mar 27, 2023 |
Apr 04, 2023 |
0.4234 |
2023 Total: |
0.7358 |
||||
2022 |
N/A |
Aug 12, 2022 |
Aug 15, 2022 |
Aug 23, 2022 |
0.2034 |
2022 |
N/A |
Mar 25, 2022 |
Mar 28, 2022 |
Apr 05, 2022 |
0.3657 |
2022 Total: |
0.5691 |
||||
2021 |
N/A |
Aug 16, 2021 |
Aug 17, 2021 |
Aug 25, 2021 |
0.1934 |
2021 |
N/A |
Mar 26, 2021 |
Mar 29, 2021 |
Apr 07, 2021 |
0.3316 |
2021 Total: |
0.5249 |
||||
2020 |
N/A |
Aug 14, 2020 |
Aug 17, 2020 |
Aug 25, 2020 |
0.1840 |
2020 |
N/A |
Mar 27, 2020 |
Mar 30, 2020 |
Apr 07, 2020 |
0.2807 |
2020 Total: |
0.4646 |
||||
2019 |
N/A |
Aug 16, 2019 |
Aug 19, 2019 |
Aug 27, 2019 |
0.1575 |
2019 |
N/A |
Mar 22, 2019 |
Mar 25, 2019 |
Apr 02, 2019 |
0.2786 |
2019 Total: |
0.4361 |